An observational study examined 18 over-the-counter (OTC) skin creams, identifying undeclared pharmacologically active ingredients (UPAIs) in six products (33.3%). Subsequent analysis of these six products confirmed the presence of UPAIs in all three tested units.
Six of the products contained clobetasol propionate at concentrations ranging from 0.01% to 0.46%, exceeding FDA-approved topical formulations by 9.2-fold. Two products also contained miconazole or terbinafine, without disclosure on product labels. The study highlighted the potential for chronic exposure to clobetasol, associated with adverse outcomes such as skin atrophy and dyspigmentation, particularly periocular exposure with glaucoma risk.
The products had significant consumer reach, with extensive online reviews. The authors suggest that regulatory and surveillance approaches are insufficient, and consumers should exercise caution with creams lacking ingredient listings. Approximately 85 million people in the U.S. suffer from skin conditions, and the inclusion of UPAIs may explain apparent efficacy while posing substantial risks without medical supervision. The study’s targeted assessment, focusing on products with efficacy claims and high consumer engagement, demonstrated the effectiveness of this approach for UPAI detection and regulatory evaluation.